Effect of Transcranial Direct-current Stimulation Therapy on Primary Chronic Insomnia Patients

September 23, 2021 updated by: Ki-Young Jung, Seoul National University Hospital

Effect of Transcranial Direct-current Stimulation Therapy on Primary Chronic Insomnia Patients: A Pilot Study.Insomnia Patients

To evaluate the clinical efficacy and safety of neuromodulation by transcranial direct current stimulation (tDCS) in the patients with primary chronic insomnia .

Study Overview

Status

Completed

Conditions

Detailed Description

  • visit 1

    • to fill in a questionnaire (Clinical Global Impression, CGI; Leeds Sleep Evaluation Questionnaire, LSEQ; Stanford Sleepiness Scale, SSS; Hospital Anxiety and Depression Scale, HADS; 36-Item Short Form Survey, SF-36)
    • EEG
  • visit 2-6

    • tDCS stimulation (monday ~ friday)
    • anodal / cathodal / sham
    • to fill in a questionnaire (CGI, LSEQ, SSS, HADS)
    • analysis the results of sleep log and actigraphy
  • visit 7 : 1 week after treatment

    • to fill in a questionnaire (CGI, LSEQ, SSS, HADS)
    • analysis the results of sleep log and actigraphy
    • EEG
  • visit 8 : 1 month after treatment

    • to fill in a questionnaire (CGI, LSEQ, SSS, HADS, SF-36)
    • analysis the results of sleep log

Study Type

Interventional

Enrollment (Actual)

8

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • adult (older than 19 years)
  • primary insomnia
  • right handed
  • agree with participation of this study

Exclusion Criteria:

  • diagnosed with epilepsy or history of seizure
  • change of antipsychotic drug within 1 month
  • under suspicion of sleep apnea or periodic limb movement disorder
  • mental retardation (IQ < 70)
  • pregnant woman

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: anodal stimulation
10 person The patients treated by anodal stimulation (2mA) for 20 minutes
Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Other Names:
  • HDCstim (direct current stimulator)
Active Comparator: cathodal stimulation
10 person The patients treated by cathodal stimulation (1-2mA) for 20 minutes
Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Other Names:
  • HDCstim (direct current stimulator)
Sham Comparator: sham stimulation
10 person The patients treated by anodal stimulation (1-2mA) for 15 seconds
Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Other Names:
  • HDCstim (direct current stimulator)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
sleep log and actiwatch
Time Frame: Change from baseline at 1 week
Changes of sleep quality
Change from baseline at 1 week

Secondary Outcome Measures

Outcome Measure
Time Frame
questionnaire
Time Frame: Change from baseline at 1 month
Change from baseline at 1 month
EEG spectrum analysis
Time Frame: Change from baseline at 1 month
Change from baseline at 1 month
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time Frame: Change from baseline at 1 month
Change from baseline at 1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Ki-Young Jung, professor, Seoul National University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 1, 2016

Primary Completion (Actual)

September 30, 2016

Study Completion (Actual)

May 1, 2017

Study Registration Dates

First Submitted

April 18, 2016

First Submitted That Met QC Criteria

July 11, 2016

First Posted (Estimate)

July 14, 2016

Study Record Updates

Last Update Posted (Actual)

September 24, 2021

Last Update Submitted That Met QC Criteria

September 23, 2021

Last Verified

September 1, 2021

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Primary Insomnia

Clinical Trials on transcranial Direct Current Stimulation

Subscribe